Thank you for subscribing.

Please check your email to confirm.

Unsubscribe success..

You already subscribed and confirmed.

Please check your email.

You already subscribed.

Please check your email to confirm.

Chinese Immuno-Oncology Firm I-Mab's IPO Lands on NASDAQ
Chinese Immuno-Oncology Firm I-Mab's IPO Lands on NASDAQ
I-Mab is the first Chinese company in two years to try the US boards for an IPO. Image: Credit to Shutterstock
Associated Company
I-Mab Bio I-Mab Bio

Chinese antibody developer I-Mab Biopharma's (IMAB) long-anticipated IPO lands on NASDAQ on 16 January, in a move to bankroll its ongoing oncological drug pipelines following the successful landing of USD 100 million. The company is the first Chinese biotech company to do so in around two years, as most of the companies from the mainland have forayed into the Hong Kong Stock Exchange, thanks to the updated regulatory approval process at the Fragrant Harbour's bourse.

The IPO date is pregnant with meaning, in the sense that it is just after JPMorgan's healthcare event in SF – healthcare private equity heavyweights have whispered for the entire week on what they think may be a lucrative deal to take.

Prior to its initial public offering, the cancer drug developer has issued over USD 300 million worth of shares to a plethora of venture capitalists and private equity arms of pharmaceutical behemoths, including Wuxi Apptec's (SH: 603259) venture capital arm and Ally Bridge Group, a new amendment onto the company's IPO filing revealed.

The company's primary market investors, Caesar Pro Holdings Limited, Wuxi Biologics, and Hongkong Tigermed, overvalued the company in its Series C-1 by offering USD 16.1 per ADS in the fall of 2019, the amendment has also revealed. The firm is expecting to price its shares within a price range of USD 12 to USD 15 by offering 7.4 million in ADS to the public.

The company sees its novel or "highly differentiated" drugs TJ202, TJ107, enoblituzumab, and TJ101, as the four anchor assets in its China Portfolio, and planning to support them by the windfall of the public funds.

China is one of the flag-carriers of cancer immunotherapy and the number of active drugs in development grew 91% between 2017-2019. I-Mab will be representing China's IO advancements in the US, and EqualOcean will keep watching this firm: as we have been doing from the get-go.

Enterprise Information

I-Mab Biopharma is a global player in innovative biologics.
CATEGORIES: Healthcare, Diabetes, Pharmaceutical Production, Biopharmaceutical, Medical, Pharmaceutical
Last Funding Type
IPO
Number of Employees
51-100
Number of Funding Rounds
5

Enterprise Information

I-Mab Bio
I-Mab Biopharma is a global player in innovative biologics.
CATEGORIES: Healthcare, Diabetes, Pharmaceutical Production, Biopharmaceutical, Medical, Pharmaceutical
Last Funding Type
IPO
Number of Employees
51-100
Number of Funding Rounds
5

Reach the Author!

Ask the author questions about the copied text

MOST READ

THE LATEST

Any Question

EqualOcean is an international information service provider and investment research firm that aims to become a global platform for industrial innovation.

We strive to make technology inclusive, accessible and transparent.

Join over 70,000 of your peers